Biotech startups that raised Series B in Beijing, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Anlong Bio | Beijing | Series B | $14.3M | 2026-01-07 |
| Huichuang Medical | Beijing | Series B | $14.1M | 2024-05-31 |
| Avistone Pharmaceuticals | Beijing | Series B | $140.7M | 2023-12-28 |
3 rows of the CSV in 5 of its 18 columns.
- The 31 biotech startups in Beijing, China whose last round is Series B have raised $615.9M in total.
- 3 of them closed their most recent round in the last 12 months, $71.5M combined.
- The largest of those rounds is KYinno's $35.5M Series B, dated December 2025.
- The most recent is Puyi Biotech's $21.8M Series B on 16 March 2026.
- Health care is the most common other sector, with 24 companies (77%).
- 3% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 51 to 100 employees (31% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
1 of 31| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Anlong Bio | Anlong Bio researches and develops nucleic acid drugs, including gene therapy, RNA drugs, and gene editing. | Biotech | Series B | $14.3M | 2026-01-07 | $14.3M | TaiKun Fund | 51 to 100 | 2019 |
Table 1. Biotech startups that raised Series B in Beijing, China: the 1 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 31.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Anlong Bio | Anlong Bio researches and develops nucleic acid drugs, including gene therapy, RNA drugs, and gene editing. | Biotech | Series B | $14.3M | 2026-01-07 | $14.3M | TaiKun Fund | 51 to 100 | 2019 |
Table 2. Biotech startups that raised Series B in Beijing, China: the 1 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | TaiKun Fund | Venture capital firm | 1 | 3% | 1 | Anlong Bio | |
| 2 | Gaorong Capital | Venture capital firm | Wangjing, China | 1 | 3% | ||
| 3 | Innoangel Fund | Venture capital firm | Beijing, China | 1 | 3% | ||
| 4 | 3E Bioventures | Venture capital firm | Beijing, China | 1 | 3% | ||
| 5 | DT Capital Partners | Private equity firm | Shanghai, China | 1 | 3% | ||
| 6 | Tsing-Yuan Capital | Venture capital firm | Shenzhen, China | 1 | 3% | ||
| 7 | Addor Capital | Venture capital firm | Nanjing, China | 1 | 3% | ||
| 8 | Tao Capital | Venture capital firm | Beijing, China | 1 | 3% | ||
| 9 | ShengJing360 | Venture capital firm | Beijing, China | 1 | 3% | ||
| 10 | Neovision Capital | Venture capital firm | Shanghai, China | 1 | 3% | ||
| 11 | Sinovation Ventures | Venture capital firm | Beijing, China | 1 | 3% | ||
| 12 | Breakthrough Capital | Venture capital firm | Nanjing, China | 1 | 3% | ||
| 13 | Grand Flight Investment | Private equity firm | Shanghai, China | 1 | 3% | ||
| 14 | Dalton Venture | Venture capital firm | Shanghai, China | 1 | 3% | ||
| 15 | Primavera Capital Group | Private equity firm | Beijing, China | 1 | 3% |
Table 3. Biotech startups that raised Series B in Beijing, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 24 | 77% | $615.9M |
| Software | 2 | 6% | $47.5M |
| Hardware | 1 | 3% | $47.5M |
Table 4. Biotech startups that raised Series B in Beijing, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 31 | 100% | $19.1M |
Table 5. Biotech startups that raised Series B in Beijing, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| March 2026 | 1 | 33% | $21.8M |
| January 2026 | 1 | 33% | $14.3M |
| December 2025 | 1 | 33% | $35.5M |
Table 6. Biotech startups that raised Series B in Beijing, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 2 | 6% | $36.0M |
| 2025 | 2 | 6% | $35.5M |
| 2024 | 2 | 6% | $28.0M |
| 2023 | 5 | 16% | $228.3M |
| 2022 | 8 | 26% | $373.5M |
| 2021 | 2 | 6% | $61.6M |
Table 7. Biotech startups that raised Series B in Beijing, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 1 | 3% |
| 2015 to 2019 | 18 | 58% |
| 2010 to 2014 | 8 | 26% |
| Before 2010 | 4 | 13% |
Table 8. Biotech startups that raised Series B in Beijing, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 1 | 3% |
| 11 to 50 | 6 | 21% |
| 51 to 100 | 9 | 31% |
| 101 to 250 | 6 | 21% |
| 251 to 500 | 4 | 14% |
| 501 to 1,000 | 1 | 3% |
| 1,001 to 5,000 | 2 | 7% |
Table 9. Biotech startups that raised Series B in Beijing, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in Beijing, China. On 16 November 2026 that is 31 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 1 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 31 rows: 5 have no round amount, 0 no city and 10 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Beijing, China whose last round is Series B are on the list?
- 31, in the file dated 16 November 2026. 3 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 31 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.